

Nitric Oxide Synthase Brain - Pipeline Review, H1 2020

<https://marketpublishers.com/r/N8EFCB1F2E58EN.html>

Date: January 2020

Pages: 42

Price: US\$ 3,500.00 (Single User License)

ID: N8EFCB1F2E58EN

Abstracts

Nitric Oxide Synthase Brain - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Nitric Oxide Synthase Brain - Pipeline Review, H1 2020'; Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Nitric oxide synthase 1 or NOS1 is an enzyme encoded by the NOS1 gene. It produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter.

The report 'Nitric Oxide Synthase Brain - Pipeline Review, H1 2020' outlays comprehensive information on the Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics development with respective

active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Infectious Disease, Oncology and Respiratory which include indications Dyskinesia, Parkinson's Disease, Neurodegenerative Diseases, Migraine, Visceral Pain, Bacterial Infections, Bladder Pain, Cardiac Arrest, Cerebral Palsy, Hypoxia, Melanoma, Musculoskeletal Pain, Neuroinflammation, Post-Operative Pain and Post-Traumatic Stress Disorder (PTSD).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)

The report reviews Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics and enlists all their major and minor projects

The report assesses Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS

or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Overview

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Companies Involved in Therapeutics Development

Eli Lilly and Co

NeurAxon Pharma Inc

Neurophoxia BV

SalubRx Therapeutics Inc

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Drug Profiles

2-Iminobiotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-87201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-188 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-462 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-613 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBX-774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Dormant Products

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Product Development Milestones

Featured News & Press Releases
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by NeurAxon Pharma Inc, H1 2020
Pipeline by Neurophyxia BV, H1 2020
Pipeline by SalubRx Therapeutics Inc, H1 2020
Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Eli Lilly and Co

NeurAxon Pharma Inc

Neurophyxia BV

SalubRx Therapeutics Inc

I would like to order

Product name: Nitric Oxide Synthase Brain - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/N8EFCB1F2E58EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N8EFCB1F2E58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970